MAPT and Alzheimer disease: They have the advantage that they are orally bioavailable and proved able to reduce tau hyper-phosphorylation in triple-transgenic mice (3 × Tg-AD) harboring mutations in presenilin1 (PS1), APP, and tau (PS1M146V, APPSwe, tauP301L) (Luo et al., 2016).